

Geert Leroux-Roels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/463429/publications.pdf>

Version: 2024-02-01

108
papers

4,212
citations

117625

34
h-index

138484

58
g-index

112
all docs

112
docs citations

112
times ranked

7215
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2022, 225, 1399-1410.	4.0	16
2	Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine. <i>Frontiers in Immunology</i> , 2022, 13, 852904.	4.8	12
3	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. <i>Lancet, The</i> , 2021, 397, 39-50.	13.7	49
4	Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6 ⁺ cell-line: a phase 1 randomized controlled trial in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1366-1373.	3.3	6
5	Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. <i>Vaccine</i> , 2021, 39, 1310-1318.	3.8	113
6	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. <i>Npj Vaccines</i> , 2021, 6, 78.	6.0	34
7	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 931-941.	1.9	79
8	Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 1271-1281.	9.1	39
9	Long-term immunogenicity and safety of a non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine: 4-year follow-up of a phase 1 multicentre trial. <i>Vaccine: X</i> , 2021, 9, 100124.	2.1	5
10	Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B <i>Streptococcus</i> Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2570-2579.	5.8	18
11	Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group ¹ . <i>Emerging Infectious Diseases</i> , 2020, 26, 2118-2128.	4.3	7
12	Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. <i>Vaccine</i> , 2020, 38, 3227-3234.	3.8	7
13	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. <i>Vaccine</i> , 2020, 38, 1678-1689.	3.8	2
14	Pregnancy has a minimal impact on the acute transcriptional signature to vaccination. <i>Npj Vaccines</i> , 2020, 5, 29.	6.0	7
15	Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1816-1825.	4.0	18
16	Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework. <i>Vaccine</i> , 2019, 37, 6144-6153.	3.8	7
17	Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1066-1075.	2.0	31
18	Safety and immunogenicity of non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine. <i>Vaccine</i> , 2019, 37, 3113-3122.	3.8	30

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. <i>Vaccine</i> , 2019, 37, 2694-2703.	3.8	30
20	Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. <i>Scientific Reports</i> , 2019, 9, 20362.	3.3	20
21	LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac [®] , [†] and Engerix B [®] (PROTECT). <i>Open Forum Infectious Diseases</i> , 2019, 6, S998-S998.	0.9	0
22	A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (Tdap) booster vaccines in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 45-58.	3.3	8
23	Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 597-607.	4.0	59
24	Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 596-608.	3.3	19
25	Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. <i>Virology</i> , 2018, 514, 30-41.	2.4	8
26	1531. A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 Is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S475-S475.	0.9	1
27	Differences in antigenic sites and other functional regions between genotype A and G mumps virus surface proteins. <i>Scientific Reports</i> , 2018, 8, 13337.	3.3	22
28	A <i>Plasmodium berghei</i> sporozoite-based vaccination platform against human malaria. <i>Npj Vaccines</i> , 2018, 3, 33.	6.0	32
29	Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in <i>Bacillus Calmette-Guérin</i> -Vaccinated Adults. <i>Frontiers in Immunology</i> , 2018, 9, 564.	4.8	33
30	Late Breaking Abstract - Safety and immunogenicity of non-typeable <i>H. influenzae</i> (NTHi) and <i>M. catarrhalis</i> (Mcat) adjuvanted vaccines in adults. , 2018, , .		0
31	Persistence of antibodies 20Ây after vaccination with a combined hepatitis A and B vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 972-980.	3.3	38
32	Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. <i>Antiviral Research</i> , 2017, 141, 150-154.	4.1	46
33	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. <i>Gut</i> , 2017, 66, 920-929.	12.1	113
34	Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. <i>Vaccine Journal</i> , 2017, 24, .	3.1	21
35	Influenza virus-specific antibody dependent cellular cytotoxicity induced by vaccination or natural infection. <i>Vaccine</i> , 2017, 35, 238-247.	3.8	49
36	A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. <i>Vaccine</i> , 2017, 35, 6700-6706.	3.8	8

#	ARTICLE	IF	CITATIONS
37	Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial. <i>Vaccine</i> , 2017, 35, 6321-6328.	3.8	25
38	A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. <i>Antiviral Research</i> , 2017, 148, 53-64.	4.1	18
39	Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG ^Δ KO Mice. <i>Methods in Molecular Biology</i> , 2017, 1506, 117-130.	0.9	17
40	Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. <i>Frontiers in Immunology</i> , 2017, 8, 943.	4.8	111
41	Safety and Immunogenicity of Different Formulations of the Takeda Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
42	A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2016, 15, 543.	2.3	10
43	Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0157385.	2.5	33
44	Monoclonal anti- ϵ envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. <i>Hepatology</i> , 2016, 63, 1120-1134.	7.3	30
45	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	3.2	90
46	Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable <i>Haemophilus influenzae</i> (NTHi) protein vaccine in adults. <i>Vaccine</i> , 2016, 34, 3156-3163.	3.8	27
47	Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and <i>post-hoc</i> correlate of protection analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3043-3055.	3.3	5
48	Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. <i>Cell</i> , 2016, 167, 643-656.e17.	28.9	373
49	<i>In vitro</i> and <i>in vivo</i> metabolism studies of dimethazine. <i>Biomedical Chromatography</i> , 2016, 30, 1202-1209.	1.7	6
50	Metabolic studies of prostanazol with the uPA-SCID chimeric mouse model and human liver microsomes. <i>Steroids</i> , 2016, 107, 139-148.	1.8	1
51	A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B <i>Streptococcus</i> vaccine for use in non-pregnant and pregnant women. <i>Vaccine</i> , 2016, 34, 1786-1791.	3.8	60
52	Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 321-330.	9.1	42
53	Adjuvanted herpes zoster subunit vaccine. <i>Future Virology</i> , 2016, 11, 5-18.	1.8	0
54	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. <i>Gut</i> , 2016, 65, 2029-2034.	12.1	21

#	ARTICLE	IF	CITATIONS
55	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE, 2016, 11, e0165384.	2.5	2
56	Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease. Open Forum Infectious Diseases, 2015, 2, ofv067.	0.9	39
57	Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1. Journal of Biological Chemistry, 2015, 290, 4022-4037.	3.4	63
58	Old and new adjuvants for hepatitis B vaccines. Medical Microbiology and Immunology, 2015, 204, 69-78.	4.8	23
59	Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model. Journal of Antimicrobial Chemotherapy, 2015, 70, 1784-7.	3.0	25
60	Immunogenicity and safety of cell-derived MF59 [®] -adjuvanted A/H1N1 influenza vaccine for children. Human Vaccines and Immunotherapeutics, 2015, 11, 358-376.	3.3	12
61	Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice. Methods in Molecular Biology, 2015, 1325, 59-68.	0.9	7
62	Safety and immunogenicity of an MF59 [®] -adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine, 2015, 33, 174-181.	3.8	21
63	Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. Vaccine, 2015, 33, 1084-1091.	3.8	42
64	Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials. Vaccine, 2015, 33, 577-584.	3.8	50
65	Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination [®] "Heplisav [®] , [¢] compared with Engerix-B [®] vaccine in adults. Vaccine, 2015, 33, 3161.	3.8	0
66	1110Identification of Formulations and Vaccine Schedules of a Trivalent Group B Streptococcus Vaccine for Further Development in Non-pregnant and Pregnant Women. Open Forum Infectious Diseases, 2014, 1, S329-S329.	0.9	0
67	Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. Journal of Infectious Diseases, 2014, 209, 1873-1881.	4.0	206
68	Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 2211-2219.	3.3	54
69	Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-na ^ï ve HIV-1-infected patients. Journal of Immunological Methods, 2014, 414, 1-10.	1.4	19
70	Genetic and Antigenic Typing of Seasonal Influenza Virus Breakthrough Cases from a 2008-2009 Vaccine Efficacy Trial. Vaccine Journal, 2014, 21, 271-279.	3.1	9
71	Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine. Vaccine Journal, 2014, 21, 302-311.	3.1	13
72	Influenza symptoms and their impact on elderly adults: randomised trial of <sc>AS</sc>03 [®] -adjuvanted or non [®] -adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza and Other Respiratory Viruses, 2014, 8, 452-462.	3.4	24

#	ARTICLE	IF	CITATIONS
73	Human Skin-Derived Precursor Cells Are Poorly Immunogenic and Modulate the Allogeneic Immune Response. <i>Stem Cells</i> , 2014, 32, 2215-2228.	3.2	16
74	Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6â€“35 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e320-e329.	2.0	12
75	A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59Â®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1701-1710.	3.3	31
76	Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. <i>Vaccine</i> , 2014, 32, 6838-6846.	3.8	56
77	Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. <i>Vaccine</i> , 2014, 32, 3694-3705.	3.8	20
78	Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses. <i>Journal of Virology</i> , 2014, 88, 5502-5510.	3.4	59
79	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with <i>in vitro</i> resistance to SR-BI-targeting agents. <i>Hepatology</i> , 2014, 60, 1508-1518.	7.3	50
80	Metabolism of methylstenbolone studied with human liver microsomes and the uPA ^{+/+} â€“CID chimeric mouse model. <i>Biomedical Chromatography</i> , 2014, 28, 974-985.	1.7	15
81	Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2014, 13, 136.	2.3	79
82	Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent <i>Plasmodium falciparum</i> infection. <i>Journal of Clinical Investigation</i> , 2014, 124, 140-144.	8.2	140
83	Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children. <i>PLoS ONE</i> , 2014, 9, e115126.	2.5	26
84	Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. <i>World Journal of Gastroenterology</i> , 2014, 20, 15975.	3.3	19
85	A genetically attenuated malaria vaccine candidate based on <i>P. falciparum</i> b9/slarp gene-deficient sporozoites. <i>ELife</i> , 2014, 3, .	6.0	68
86	In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). <i>Forensic Toxicology</i> , 2013, 31, 212-222.	2.4	25
87	AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 485-496.	9.1	143
88	<i>In vivo</i> and <i>in vitro</i> metabolism of the synthetic cannabinoid JWH-200. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 2115-2126.	1.5	41
89	Molecular detection and quantification of <i>Plasmodium falciparum</i> -infected human hepatocytes in chimeric immune-deficient mice. <i>Malaria Journal</i> , 2013, 12, 430.	2.3	19
90	Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. <i>Vaccine</i> , 2013, 31, 3739-3746.	3.8	34

#	ARTICLE	IF	CITATIONS
91	Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. <i>Vaccine</i> , 2013, 31, 2196-2206.	3.8	135
92	Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1254-1262.	3.3	18
93	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. <i>PLoS ONE</i> , 2013, 8, e55438.	2.5	69
94	Blocking HCV entry as potential antiviral therapy. <i>Future Virology</i> , 2012, 7, 547-561.	1.8	7
95	Head-to-head comparison of pandemic influenza vaccines. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 74-75.	9.1	3
96	Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted Cervical Cancer Vaccine. <i>Vaccine Journal</i> , 2011, 18, 1510-1518.	3.1	18
97	Unmet needs in modern vaccinology. <i>Vaccine</i> , 2010, 28, C25-C36.	3.8	257
98	Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1057-1071.	3.1	64
99	Hepatitis B vaccines: accomplishments, shortcomings, and future developments. <i>The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2008, 23, 33-37.	0.2	1
100	The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. <i>Journal of General Virology</i> , 2005, 86, 75-84.	2.9	34
101	Development of prophylactic and therapeutic vaccines against hepatitis C virus. <i>Expert Review of Vaccines</i> , 2005, 4, 351-371.	4.4	12
102	Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. <i>Journal of General Virology</i> , 2005, 86, 323-331.	2.9	18
103	A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. <i>Vaccine</i> , 2004, 22, 3080-3086.	3.8	74
104	Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. <i>Journal of General Virology</i> , 2002, 83, 1281-1289.	2.9	42
105	LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. <i>Journal of General Virology</i> , 2002, 83, 2279-2289.	2.9	39
106	Characterization of HLA DR13-restricted CD4+ T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. <i>Journal of General Virology</i> , 2002, 83, 3023-3033.	2.9	15
107	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. , 2000, 60, 126-132.		17
108	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. <i>Journal of Medical Virology</i> , 2000, 60, 126.	5.0	1